Trials / Completed
CompletedNCT00458822
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Risk-Adapted Intravenous Melphalan With Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients With Systemic Light-Chain (AL) Amyloidosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study in patients needing treatment for AL amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan treatment, to see how well treatment with bortezomib and dexamethasone works to reduce the rest of the clonal plasma cell disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bortezomib | Given IV |
| DRUG | dexamethasone | Given orally |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2007-04-11
- Last updated
- 2016-08-10
- Results posted
- 2016-08-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00458822. Inclusion in this directory is not an endorsement.